scholarly journals Evaluation of Fractional Exhaled Nitric Oxide in Pediatric Asthma and Allergic Rhinitis

Children ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 3
Author(s):  
Yoon Young Jang ◽  
Ji Young Ahn

Fractional exhaled nitric oxide (FeNO) is a non-invasive test for evaluating the degree of airway inflammation and for the diagnosis, evaluation, and treatment of asthma. We attempted to measure FeNO levels in Korean children with asthma and determine its cutoff value for diagnosing asthma. We enrolled 176 children and adolescents between the ages of 5 and 18 years, who visited for the evaluation of chronic cough, shortness of breath, and wheezing. Among them, 138 patients who underwent skin prick tests or inhalation Immuno CAP (UniCAP; Pharmacia, Uppsala, Sweden) tests for allergy testing together with a pulmonary function test were included. FeNO was measured using a NIOX MINO (Aerocrine AB, Solna, Sweden) instrument according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. There were 29 patients with asthma, 43 with rhinitis, and 38 with asthma and allergic rhinitis. In the asthma group, FeNO levels significantly correlated with total immunoglobulin E (r = 0.572, p < 0.001), but did not show significant correlation with pulmonary function test parameters (forced vital capacity—FVC, forced expiratory volume in one second—FEV1, FEV1/FVC) or PC20 (provocative concentration of methacholine causing a 20% fall in FEV1). The FeNO cutoff values obtained in the asthma and asthma rhinitis groups were 16.5 ppb and 18.5 ppb, respectively. Hence, we provide a FeNO cutoff value according to the presence or absence of rhinitis in pediatric patients with asthma.

2008 ◽  
Vol 51 (2) ◽  
pp. 181 ◽  
Author(s):  
Han-Seok Ko ◽  
Sung-Hoon Chung ◽  
Yong-Sung Choi ◽  
Sun-Hee Choi ◽  
Yeong-Ho Rha

2015 ◽  
Vol 3 (6) ◽  
pp. 439 ◽  
Author(s):  
Seung Hyun Moon ◽  
Hae Ji Jang ◽  
Yoon Sung Park ◽  
Woo Yeon Lee ◽  
Dae Hyun Lim ◽  
...  

Acta Medica ◽  
2020 ◽  
Vol 51 (4) ◽  
pp. 41-47
Author(s):  
Guzin Ozden ◽  
Pelin Duru Cetinkaya

Objective: We aimed to evaluate our patient’s treatment responses to three-month immunotherapy for allergic rhinitis with or without asthma, and to investigate the factors affecting treatment Material and Methods: A total of 53 patients receiving subcutaneous immunotherapy for allergic rhinitis with or without asthma were included in the study. All patients were positive for mite skin prick test. Asthma was present as a concomitant disease in 28(52.8%) patients. Patients with and without asthma were classified in two groups as “Allergic rhinitis + Asthma+” and “Allergic rhinitis+ Asthma-“. The values of pulmonary function tests of all patients, and in rhinitis with asthma patients, the Asthma Control Test scores before and after three months of treatment were recorded. Results: In “Allergic rhinitis + Asthma+” and “Allergic rhinitis + Asthma-“groups, male/female ratio was 7/21 and 10/15, mean age was 33±9 and 32±9 years. No statistically significant differences were present between the pre-treatment and 3-month-treatment values of pulmonary function test. The difference between the pre-treatment and 3-month treatment asthma control test scores was strongly significant. Conclusion: In allergic rhinitis, which is quite commonly associated with asthma, the control of asthma is also provided with the treatment of allergic rhinitis. By using pulmonary function test in allergic rhinitis and asthma control test in asthma, we showed that the effectiveness of allergen specific immunotherapy started in 3 months which was earlier from current literature.


Sign in / Sign up

Export Citation Format

Share Document